Evidence map›Paper›PMID 30246707›Full record

ArticleAsian journal of andrology

The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience.

Run-Zhuo Ma, Lei Tian, Li-Yuan Tao, Hui-Ying He, Min Li, Min Lu, Lu-Lin Ma, Hui Jiang, Jian Lu

Abstract read
In one paragraph

Article in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Mutation ofJournal of inflammation research · 2022
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Run-Zhuo MaDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Lei TianDepartment of Hematology, Peking University Third Hospital, Beijing 100191, China.
Li-Yuan TaoDepartment of Biostatistics, Peking University Third Hospital, Beijing 100191, China.
Hui-Ying HeDepartment of Pathology, Peking University Third Hospital, Beijing 100191, China.
Min LiDepartment of Pathology, Peking University Third Hospital, Beijing 100191, China.
Min LuDepartment of Pathology, Peking University Third Hospital, Beijing 100191, China.
Lu-Lin MaDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Hui JiangDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Jian LuDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to investigate the effect of different local testicular treatments and validate common prognostic factors on primary testicular lymphoma (PTL) patients. We retrospectively reviewed the clinical records of 32 patients from 1993 to 2017 diagnosed with PTL and included 22 patients for analysis. The Kaplan-Meier method, Log-rank test, and multivariate Cox proportional hazard regression analysis were applied to evaluate progression-free survival (PFS), overall survival (OS), and determine prognosis predictors. The median follow-up time was 30 months. Median OS and PFS were 96 months and 49 months, respectively. In univariate analysis, advanced Ann Arbor stage (III/IV) (P < 0.001), B symptoms (P < 0.001), and extranodal involvement other than testis (P = 0.001) were significantly associated with shorter OS and PFS. In multivariate analysis, Ann Arbor stage was significantly associated with OS (OR = 11.58, P = 0.049), whereas B symptom was significantly associated with PFS (OR = 11.79, P= 0.049). In the 10 patients with the systemic usage of rituximab, bilateral intervention could improve median OS from 16 to 96 months (P = 0.032). The study provides preliminary evidence on bilateral intervention in testes in the rituximab era and validates common prognostic factors for Chinese PTL patients.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsAsian PeopleChinaHumansKaplan-Meier EstimateLymphomaMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesRituximabSurvival AnalysisTesticular NeoplasmsAntineoplastic AgentsRituximablocal treatment modalitiesprognostic factorsprophylaxis contralateral orchiectomyprophylaxis contralateral radiotherapytesticular lymphoma

Identifiers

PMID30246707
PMCPMC6219299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.